Suv39h1-KO Mouse
Common Name
Suv39h1-KO
제품 ID
S-KO-04662
Backgroud
C57BL/6NCya
품종 계통계통 ID
KOCMP-20937-Suv39h1-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Suv39h1-KO Mouse (카탈로그 번호 S-KO-04662)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Suv39h1-KO
품종 계통계통 ID
KOCMP-20937-Suv39h1-B6N-VA
유전자명
제품 ID
S-KO-04662
유전자 별칭
mIS6, KMT1A, DXHXS7466e, H3-K9-HMTase 1
배경
C57BL/6NCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr X
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000115638
NCBI 전사체 ID
NM_011514
타겟 영역
Exon 2~3
유효 영역 크기
~1.9 kb
유전자 연구 개요
Suv39h1, a lysine methyltransferase, is known for its role in introducing di-and trimethylation at histone H3 lysine 9 (H3K9). It is crucial in maintaining heterochromatin and gene repression, and is involved in various biological processes [6]. Genetic models, such as KO and CKO mouse models, have been valuable in studying its functions.
In liver fibrosis, HSC-specific or myofibroblast-specific deletion of Suv39h1 in mice ameliorated liver fibrosis. Suv39h1 inhibition by chaetocin also mitigated liver fibrosis in mice. Mechanistically, Suv39h1 bound to the promoter of heme oxygenase 1 (HMOX1) and repressed its transcription [1]. In adoptive T-cell therapies, genetic disruption of SUV39H1 enhanced the early expansion, long-term persistence, and overall antitumor efficacy of human CAR T cells in leukemia and prostate cancer models [2]. Also, in solid tumor models, inactivation of SUV39H1 enhanced BBz-CAR T cell long-term persistence, protecting mice against tumor relapses and rechallenges [3]. In limb ischemia of mice, pharmaceutical inhibition or genetic deletion of SUV39H1 significantly improved blood perfusion, capillary density, and angiogenesis in ischemic muscle tissue [4]. In liver ischemia-reperfusion injury, global or hepatocyte conditional Suv39h1 KO mice were protected from liver I/R injury, and a small-molecule SUV39H1 inhibitor achieved similar hepatoprotective effects [5]. In MLL-AF9-induced AML, Suv39h1 overexpression increased leukemia latency and decreased the frequency of LSCs, while Suv39h1 knockdown accelerated disease progression [7]. In glioblastoma, knockdown of SUV39H1 in patient-derived GSCs impaired their proliferation and stemness, and treatment with a SUV39H1 inhibitor sensitized GSCs to temozolomide [8].
In conclusion, Suv39h1 plays essential roles in multiple biological processes and diseases. Model-based research, especially through Suv39h1 KO/CKO mouse models, has revealed its significance in liver fibrosis, adoptive T-cell therapies for cancer, limb ischemia, liver ischemia-reperfusion injury, AML, and glioblastoma. Understanding Suv39h1 functions provides potential therapeutic targets for these disease areas.
References:
1. Kong, Ming, Zhou, Junjing, Kang, Aoqi, Xu, Yong, Li, Zilong. 2024. Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis. In Gut, 73, 810-824. doi:10.1136/gutjnl-2023-329671. https://pubmed.ncbi.nlm.nih.gov/38176898/
2. Jain, Nayan, Zhao, Zeguo, Koche, Richard P, Giavridis, Theodoros, Sadelain, Michel. . Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function. In Cancer discovery, 14, 142-157. doi:10.1158/2159-8290.CD-22-1319. https://pubmed.ncbi.nlm.nih.gov/37934007/
3. López-Cobo, Sheila, Fuentealba, Jaime R, Gueguen, Paul, Saitakis, Michael, Amigorena, Sebastian. . SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors. In Cancer discovery, 14, 120-141. doi:10.1158/2159-8290.CD-22-1350. https://pubmed.ncbi.nlm.nih.gov/37934001/
4. Niu, Wenhao, Cao, Wenyue, Wu, Feng, Liang, Chun. . SUV39H1 Inhibits Angiogenesis in Limb Ischemia of Mice. In Cell transplantation, 32, 9636897231198167. doi:10.1177/09636897231198167. https://pubmed.ncbi.nlm.nih.gov/37811706/
5. Li, Zilong, Li, Jichen, Wu, Meng, Qin, Lei, Fan, Zhiwen. 2024. Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury. In Redox biology, 78, 103414. doi:10.1016/j.redox.2024.103414. https://pubmed.ncbi.nlm.nih.gov/39603205/
6. Weirich, Sara, Khella, Mina S, Jeltsch, Albert. 2021. Structure, Activity and Function of the Suv39h1 and Suv39h2 Protein Lysine Methyltransferases. In Life (Basel, Switzerland), 11, . doi:10.3390/life11070703. https://pubmed.ncbi.nlm.nih.gov/34357075/
7. Chu, Yajing, Chen, Yangpeng, Guo, Huidong, Shi, Jun, Yuan, Weiping. 2020. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. In Oncogene, 39, 7239-7252. doi:10.1038/s41388-020-01495-6. https://pubmed.ncbi.nlm.nih.gov/33037410/
8. Li, Chunying, Xie, Qiqi, Ghosh, Sugata, Nephew, Kenneth P, Shen, Jia. 2024. SUV39H1 Preserves Cancer Stem Cell Chromatin State and Properties in Glioblastoma. In bioRxiv : the preprint server for biology, , . doi:10.1101/2024.08.15.607856. https://pubmed.ncbi.nlm.nih.gov/39229036/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
